Immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma: current status and future explorations

Fu-rong KOU,Wei LIU

DOI: https://doi.org/10.16073/j.cnki.cjcpt.2017.15.014

2017-01-01

Abstract:OBJECTIVE Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide.Recurrent or metastatic (R/M) HNSCC have rare treatment methods with poor prognosis.Recently,immunotherapy,especially immune checkpoint inhibitors,has make great breakthrough in solid tumors such as melanoma and lung cancer.This review was to summarize the current status and perspectives of immunotherapy in R/M HNSCC.METHODS Two hundred and twenty-two related papers and clinical trails were searched with "head and neck squamous cell carcinoma,immunotherapy,immune checkpoint inhibitors,adoptive cell transfer,tumor vaccine" as key words within PubMed or CNKI database retrieval system and ClinicalTrials.gov website from January 2001 to January 2017,and 38 were finally selected according to the inclusion criteria as follows:(1) R/M HNSCC；(2) current status and future perspective of immunotherapy;(3) immunotherapy related clinical trials.RESULTS Researches of immunotherapy in R/M HNSCC immunotherapy have developed wildly and deepened gradually,especially immune checkpoint inhibitors.Programmed cell death-1(PD-1) inhibitors (pembrolizumab and nivolumab) showed obvious effect,and were approved by food and drug administration (FDA) for the treatment of R/M HNSCC.Although there are no results of phase 3 clinical trials related to other immune checkpoint inhibitors,such as programmed death ligand-1 (PD-L1) inhibitors (durvalumab and avelumab) and Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors (ipilimumab and tremelimumab)published,a series of clinical trials are ongoing.The modes of adoptive cell transfer and tumor vaccine are explored.Besides,many aspects of immunotherapy in R/M HNSCC,such as screening patients according to biomarkers,improving efficacy with combination methods,monitoring and treatment of adverse events also catch our attentions.CONCLUSIONS Immunotherapy has a bright prospect in R/M HNSCC,but there are also many challenges.Future studies should focus on how to screen the most effective population,explore immune treatment modes and improve the efficacy of immunotherapy.